Clinical Trials Logo

Lymphocyte Depletion clinical trials

View clinical trials related to Lymphocyte Depletion.

Filter by:
  • None
  • Page 1

NCT ID: NCT04273893 Active, not recruiting - Clinical trials for Lymphocyte Depletion

Lymphocyte Depletion and Change in Lymphocyte Functionality

Start date: February 12, 2020
Phase: N/A
Study type: Interventional

Lymphocytes are a type of white blood cell (WBC) found in the participant's blood. During radiation treatment, moving blood is exposed to radiation. This may cause a decrease in the amount of lymphocytes. A researcher at UVA has created a system to predict and reduce the immune cell reduction following lung SBRT treatments beyond standard of care tx in lymphocytes in patients with Non-Small Cell Lung Cancer (NSCLC). The predicted decrease of lymphocytes will be compared to the actual decrease in lymphocytes found in blood. Researchers have found a way to give radiation that they think will result in a smaller decrease in lymphocytes after radiation. There will be two groups in this study, about half of the participants will have their radiation designed to decrease radiation to organs with a lot of blood and the other half will receive standard radiation therapy. Participants are being asked to take part in this study because the participants have been diagnosed with NSCLC and will be receiving a type of radiation therapy called stereotactic body radiation therapy (SBRT) where high doses of radiation will be delivered to the tumor, while minimizing damage to healthy surrounding tissues.

NCT ID: NCT00305149 Completed - Clinical trials for Classical Hodgkin Lymphoma

Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma

Start date: July 1999
Phase: N/A
Study type: Interventional

.This study is trying to address change of chemotherapy dosage according to individual patient response to initial cycles of chemotherapy in order to reduce cumulative dose of chemotherapy.The study includes patients with early unfavorable and advanced hodgkin lymphoma. Patients with low risk were started with standard beacopp and only high risk patients were started with escalated beacopp.Following 2 cycles of therapy the patients were reassessed.Based on scintigraphy results decision was made regarding further therapylative chemotherapy for early responders and maximize dose intensity for late responders.